Sort   by:  
 Page size 
UnknownReply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
Not available
S-EPMC5396114 | biostudies-literature
UnknownOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Not available
S-EPMC5706778 | biostudies-literature
UnknownMethylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Not available
S-EPMC6162272 | biostudies-literature
UnknownAmyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
Not available
S-EPMC4553028 | biostudies-literature
UnknownFactors associated with D-dimer levels in HIV-infected individuals.
Not available
S-EPMC3953205 | biostudies-literature
UnknownGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Not available
S-EPMC4835977 | biostudies-literature
UnknownInterleukin-2 therapy in patients with HIV infection.
Not available
S-EPMC2869083 | biostudies-literature
UnknownDevelopment and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
Not available
S-EPMC4380415 | biostudies-literature
UnknownSeverity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.
Not available
S-EPMC4309077 | biostudies-literature
UnknownTwo phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Not available
S-EPMC4159618 | biostudies-literature
Sort   by:  
 Page size